Immunotherapy combined with antiangiogenic therapy as third‐ or further‐line therapy for stage IV non‐small cell lung cancer patients with ECOG performance status 2: A retrospective study

Documents similaires

• Immune checkpoint inhibitors combined with anti‐angiogenic therapy as second‐ or further‐line treatment for small cell lung cancer: Efficacy, safety, and prognostic biomarkers
  par: Tong Chen, et autres
  Publié: (2025)
• Impact of sarcopenia on the prognosis of patients with advanced non‐small cell lung cancer treated with antiangiogenic therapy: A propensity score matching analysis
  par: Fuchun Huang, et autres
  Publié: (2024)
• Conversion therapy with sintilimab combined with chemotherapy and apatinib in stage IV gastric cancer
  par: Yong Liu, et autres
  Publié: (2025)
• Prolonged inhibition of intratumoral mast cells enhances efficacy of low‐dose antiangiogenic therapy
  par: Nikolaus Berenbrok, et autres
  Publié: (2024)
• Combination therapy using low‐dose anlotinib and immune checkpoint inhibitors for extensive‐stage small cell lung cancer
  par: Han Li, et autres
  Publié: (2024)